182 related articles for article (PubMed ID: 27133817)
1. Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
Maurer C; Langerbeins P; Bahlo J; Cramer P; Fink AM; Pflug N; Engelke A; von Tresckow J; Kovacs G; Stilgenbauer S; Wendtner CM; Müller L; Ritgen M; Seiler T; Fischer K; Hallek M; Eichhorst B
Leukemia; 2016 Oct; 30(10):2019-2025. PubMed ID: 27133817
[TBL] [Abstract][Full Text] [Related]
2. First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Sylvan SE; Asklid A; Johansson H; Klintman J; Bjellvi J; Tolvgård S; Kimby E; Norin S; Andersson PO; Karlsson C; Karlsson K; Lauri B; Mattsson M; Sandstedt AB; Strandberg M; Österborg A; Hansson L
Haematologica; 2019 Apr; 104(4):797-804. PubMed ID: 30467205
[TBL] [Abstract][Full Text] [Related]
3. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
da Cunha-Bang C; Rostgaard K; Andersen MA; Rotbain EC; Grønbaek K; Frederiksen H; Niemann CU; Hjalgrim H
Br J Haematol; 2021 Apr; 193(2):339-345. PubMed ID: 33570184
[TBL] [Abstract][Full Text] [Related]
4. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
5. Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Dörfel S; Meyer D; Grugel R; Münz M; Hartmann H; Marschner N
Hematol Oncol; 2015 Mar; 33(1):15-22. PubMed ID: 24733536
[TBL] [Abstract][Full Text] [Related]
6. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
Cramer P; Isfort S; Bahlo J; Stilgenbauer S; Döhner H; Bergmann M; Stauch M; Kneba M; Lange E; Langerbeins P; Pflug N; Kovacs G; Goede V; Fink AM; Elter T; Fischer K; Wendtner CM; Hallek M; Eichhorst B
Haematologica; 2015 Nov; 100(11):1451-9. PubMed ID: 26315931
[TBL] [Abstract][Full Text] [Related]
7. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
[TBL] [Abstract][Full Text] [Related]
8. Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
Zoellner AK; Höhler T; Fries S; Böhme A; Kiewe P; Kellermann L; Dreyling M
Ann Hematol; 2016 May; 95(6):853-61. PubMed ID: 27021305
[TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
10. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Cramer P; Langerbeins P; Eichhorst B; Hallek M
Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
12. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
Niederle N; Megdenberg D; Balleisen L; Heit W; Knauf W; Weiß J; Freier W; Hinke A; Ibach S; Eimermacher H
Ann Hematol; 2013 May; 92(5):653-60. PubMed ID: 23340738
[TBL] [Abstract][Full Text] [Related]
14. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
Jain N; Balakrishnan K; Ferrajoli A; O'Brien SM; Burger JA; Kadia TM; Cortes JE; Ayres ML; Tambaro FP; Keating MJ; Gandhi V; Wierda WG
Oncotarget; 2017 Mar; 8(13):22104-22112. PubMed ID: 27655665
[TBL] [Abstract][Full Text] [Related]
15. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
17. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
[TBL] [Abstract][Full Text] [Related]
18. The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
Else M; Wade R; Oscier D; Catovsky D
Br J Haematol; 2016 Jan; 172(2):228-37. PubMed ID: 26457986
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.
Al-Sawaf O; Bahlo J; Robrecht S; Fischer K; Herling CD; Hoechstetter M; Fink AM; von Tresckow J; Langerbeins P; Cramer P; Stilgenbauer S; Wendtner CM; Eichhorst B; Hallek M; Goede V
Br J Haematol; 2018 Dec; 183(5):727-735. PubMed ID: 30460980
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
Knauf WU; Lissitchkov T; Aldaoud A; Liberati AM; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Merkle K; Montillo M
Br J Haematol; 2012 Oct; 159(1):67-77. PubMed ID: 22861163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
